Orladeyo Patent Infringement Lawsuit Status in March 2025
As of March 2025, the patent landscape surrounding BioCryst Pharmaceuticals' Orladeyo (berotralstat) involves ongoing considerations for potential patent infringement and the expiration of market exclusivity. While specific details of active infringement lawsuits can be complex and may not always be publicly disclosed in advance, the general status of patent protection and the timeline for potential generic competition are key factors for stakeholders.
When Does Orladeyo's Exclusivity Expire?
Orladeyo, a once-daily oral therapy for the preventive treatment of hereditary angioedema (HAE), has several layers of intellectual property protection. The initial U.S. patent for berotralstat is listed in the Orange Book with an expiration date in 2035 [1]. However, other patents related to formulations, methods of use, or manufacturing processes may exist, potentially extending exclusivity or becoming subjects of legal challenges. Market exclusivity periods granted by regulatory bodies, such as the five-year New Chemical Entity (NCE) exclusivity in the U.S., also play a role, though these are separate from patent terms.
Can Biosimilars Enter Before Patent Expiry?
The entry of biosimilars or generics is typically dependent on patent expiration and the successful navigation of regulatory pathways. For biosimilars, the Hatch-Waxman Act in the U.S. provides a framework for abbreviated approval. However, complex patent litigation can delay or prevent market entry. Companies seeking to market generic or biosimilar versions of Orladeyo would need to demonstrate to the U.S. Food and Drug Administration (FDA) that their product is highly similar to the reference product and that there are no significant differences in safety, purity, and potency. Any active patent litigation could directly impact these timelines.
What Are Companies Challenging Orladeyo's Patents?
While specific companies and their legal strategies are often not public knowledge until litigation is filed, it is common for generic or biosimilar manufacturers to challenge existing patents they believe are invalid or not infringed by their proposed product. These challenges are often initiated as part of the Paragraph IV certification process under the Hatch-Waxman Act, where a generic applicant notifies the patent holder that they believe their proposed drug does not infringe a listed patent or that the patent is invalid. DrugPatentWatch.com tracks patent filings and litigation, providing insights into potential challenges [1].
How Does Orladeyo's Patent Protection Compare to Other HAE Treatments?
The patent protection for Orladeyo is part of a broader landscape of intellectual property for HAE treatments. Other HAE therapies, including monoclonal antibodies like Takhzyro (lanadelumab) and CSL830 (garadacimab), also have their own patent portfolios and exclusivity periods. The longevity and strength of these patents can influence the market dynamics and the timing of generic or biosimilar competition for each drug. Analyzing patent filings and expiration dates through resources like DrugPatentWatch.com can provide a comparative view of the intellectual property for various HAE medications [1].
What Are the Risks for BioCryst if Patents are Challenged?
BioCryst faces risks if its Orladeyo patents are successfully challenged. A successful challenge could lead to early generic competition, significantly reducing market share and revenue. Litigation itself is costly and can divert resources and management attention. Furthermore, adverse legal outcomes can set precedents that affect other patents within the company's portfolio. The uncertainty surrounding patent litigation can also impact investor confidence and the company's stock valuation.
What Information is Available on Orladeyo's Clinical Data?
Orladeyo's efficacy and safety have been established through clinical trials. The drug's approval was based on its demonstrated ability to reduce the frequency of HAE attacks. Patients and healthcare providers often refer to clinical trial results, including data on attack reduction rates, adverse events, and quality-of-life improvements, when evaluating treatment options. Detailed clinical data is typically available through peer-reviewed publications and regulatory agency documents.
---
Sources:
1. DrugPatentWatch.com